Non invasive insulins: Advanced insulin therapy over this decade

Journal of Applied Pharmaceutical Science

Volumn 1, Issue 8, 2011, Pages 12-20

  Rajeswari, T S ^a  

^a Malla reddy college of pharmacy Maisammaguda ^*  (India)

Author keywords

Absorption Enhancers; Hydrogels; Ketoacidosis; Liposomes; Microspheres; Niosomes; Subcutaneous

Indexed keywords

EID: 84872974035     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: None     Document Type: Article

References (114)

1. A. Cilek, N. Celebi, F. Tirnaksiz, A. Tay, Lecithin-based microemulsions of rhinsulin with aprotinin for oral administration: investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats, Int. J. Pharm:2005;298: 176-185.
2. A. Hussain, T. Yang, A.A. Zaghloul, F. Ahsan, Pulmonary absorption of insulin mediated by tetradecyl-beta-maltoside and dimethylbeta- cyclodextrin, Pharm. Res:2003;20:1551-1557
3. A. Yamamoto, T. Taniguchi, K. Rikyuu, et al., Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats, Pharm. Res: 1994; 11: 1496-1500.
4. Abbas Pardakhty, Jaleh Varshosaz, Abdolhossein Rouholamini. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. International Journal of Pharmaceutics: 2007;328 :130-141
5. Amit Kumar, Sitanshu S. Lahiri, Harpal Singh. Development of PEGDMA: MAA based hydrogel microparticles for oral insulin delivery. International Journal of Pharmaceutics: 323:117-124
6. Arangoa, M.A., Ponchel, G., Orecchioni, A.M., Renedo, M.J., Duchene, D., Irache, J.M. Bioadhesive potential of gliadin nanoparticulate systems. Eur. J. Pharm. Sci: 2000; 11:333-334.
7. Ashada, H., Douen, T., Mizokoshi, Y., Fujita, T., Murakami, M., Yamamoto, A., Muranishi, S.Absorption characteristics of chemically modified insulin derivatives with various fatty acids in the small and large intestine. J. Pharm. Sci.:1995; 84: 682-687.
8. Aungst, B.J. Site dependence and structure-effect relationships for alkylglycosides as transmucosal absorption promoters for insulin. Int. J. Pharm. :1994 ;105: 219-225
9. B. Sarmento, D.C. Ferreira, L. Jorgensen, M. van de Weert. Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics :2007;65: 10-17
10. Bell, C.L., Peppas, N.A. Water, solute and protein diffusion in physiologically responsive hydrogels of poly (methacrylic acid-g-ethylene glycol). Biomaterials: 1996; 17: 1203-1218.
11. Blanchette, J., Park, K., Peppas, N.A. Use of complexation hydrogels for oral administration of chemotherapeutic agents. Trans. Soc. Biomat.:2003; 29:246.
12. C. Damge, C. Michel, M. Aprahamian, P. Couvrerur, New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier, Diabetes :1998;13: 246-251
13. Carino GP, Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev :1999;35(2-3):249-257.
14. Coudhari, K.B., Labhasetwar, V., Dorle, A.K. Liposomes as carrier for oral administration of insulin: effect of formulation factors. J. Microencapsul. :1994; 11:319-325
15. Cui, F., Shi, K., Zhang, L., Tao, A., Kawashima, Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control. Release: 2006; 114:242-250.
16. D.A.Lewis and H.O.Alpar,Therapeutical possibilities of Drug Encapsulate in Erythrocytes, Int. J.pharm.:1984;22:137-146
17. DR. Owens, New horizons-alternative routes for insulin therapy, Nat. Rev., Drug Discov.:2002;1: 529-540.
18. Damagè, C., Vrankx, H., Balsschmidt, P., Couvreur, P. Poly (alkyl cianoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci.:1999; 86: 1403-1409.
19. des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release.:2006; 116: 1-27
20. Drews, J. Strategic trends in drug industry. Drug Discovery Today: 2003; 8: 411-420.
21. E.A. Hosny, H.I. Al-Shora, M.M.A. Elmazar, Effect of different bile salts on the relative hypoglycemia of Witepsol W35 suppositories containing insulin in diabetic beagle dogs, Drug Dev. Ind. Pharm.: 2001; 27:837-845.
22. E.A. Hosny, Relative hypoglycemia of rectal insulin suppositories containing deoxycholic acid, sodium taurocholate, polycarbophil, and their combinations in diabetic rabbits, Drug Dev. Ind. Pharm.:1999;25: 745-752.
23. E.M. Lane, C.M. O'driscoll, O.I. Corrigan, Quantitative estimation of the effects of bile salts surfactant systems on insulin stability and permeability in the rat intestine using a mass balance model, J. Pharm. Pharmacol. :2005;27:169-175
24. Ehab A Hosny, Hassan I Al-Shora, Mohamed MA Elmazar. Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs, International Journal of Pharmaceutics: 2002; 237, Issues 1-2, 71-76
25. F.G. Banting, C.H. Best, J.B. Collip, W.R. Campbell, A.A. Fletcher, Pancreatic extracts in the treatment of diabetes mellitus, Preliminary report, Can. Med. Assoc. J. :1922;12 :141-146.
26. F.P. Kennedy, Recent developments in insulin delivery techniques: current status and future potential, Drugs: 1991; 42: 213-227.
27. Fan, Y.F.,Wang, Y.N., Fan, Y.G., Ma, J.B. Preparation of insulin nanoparticles and their encapsulation with biodegradable polyelectrolytes via the layer-by-layer adsorption. Int. J. Pharm.:2006; 324: 158-167.
28. G. Gwinup, A.N. Elias, N.D. Vaziri, A case for oral insulin therapy in the prevention of diabetic micro- and macroangiopathy, Int. J. Artif. Organs: 1990; 13:393-395.
29. G. Sharma, K. Wilson a, C.F. van der Walle, N. Sattar, J.R. Petrie, M.N.V. Ravi Kumar. Microemulsions for oral delivery of insulin. Design, development and evaluation in streptozotocin induced diabetic rats. European Journal of Pharmaceutics and Biopharmaceutics:2010;76:159-169
30. Gordon-Still, J. Development of oral insulin: progress and current status. Diabetes Metab. Res. Rev.:2002; 18: S29-S37.
31. H. Takeuchi, H. Yamamoto, T. Niwa, T. Hino, Y. Kawashima, Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes, Pharm. Res. :1996;13:896-901
32. H. Tozaki, J. Nishioka, J. Komoike, N. Okada, T. Fujita, S. Muranishi, S.I. Kim, H. Terashima, A. Yamamoto, Enhanced absorption of insulin and (Asu1,7)eel-calcitonin using novel azopolymer-coated pellets for colonspecific drug delivery, J. Pharm. Sci. :2001; 90 :89-97.
33. H.A. Krauland, D. Guggi, A. Bernkop-Schnurch, Thiolated chitosan microparticles: a vehicle for nasal peptide drug delivery, Int. J. Pharm. :2006;307: 270-277.
34. H.B. Xu, K.X. Huang, Y.S. Zhu, Q.H. Gao, Q.Z. Wu, W.Q. Tian, X.Q. Sheng, Z.X. Chen, Z.H. Gao, Hypoglycaemic effect of a novel insulin buccal formulation on rabbits, Pharmacol. Res.:2002; 46: 459-467.
35. Hamman, J.H., Enslin, G.M., Kotze, A.F. Oral delivery of peptide drugs-barriers and developments. Biodrugs.: 2005; 19 (3):165- 177.
36. Haupt, S., Rubinstein, A. The colon as a possible target for orally administered peptide and protein drugs. Crit. Rev. Ther. Drug Deliv. Syst. :2002;19: 499-551
37. Iwanaga, K., Ono, S., Narioka, K., Kakemi, M., Morimoto, K., Yamashita, S., Namba, Y., Oku, N.Application of surface coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J. Pharm. Sci.:1999;88:248-252.
38. Iwanaga, K., Ono, S., Narioka, K., Kakemi, M., Morimoto, K., Yamashita, S., Namba, Y., Oku, N. Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J. Pharm. Sci.:1999; 88: 248-252.
39. Jung, T., Kamm, W., Breitenbach, A., Kaiserling, E., Xiao, J.X., Kissel, T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. :2000; 50:147-160
40. K, Gowthamarjan, T.G. Kulkarni, Oral insulin-fact or fiction, possibilities of achieving oral delivery of insulin, Resonance.: 2003; 1-10.
41. K. Katayama, Y. Kato, H. Onishi, T. Nagai, Y.Machida, Double liposomes. hypoglycemic effects of liposomal insulin on normal rats, Drug Dev Ind. Pharm.: 2003;29:725-731
42. K. Surendrakumar, G.P. Martyn, E.C.M. Hodgers, M. Jansen, J.A. Blair, Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs, J. Control. Release: 2003; 91:385-394.
43. Kim, A., Yun, M.-O., Oh, Y.-K., Ahn, W.-S., Kim, C.-K. Pharmacodynamics of insulin in polyethylene glycol-coated liposomes. Int. J. Pharm.:1999; 180:75-81.
44. Kim, B., Peppas, N.A., Complexation phenomena in pHresponsive copolymer networks with pendent saccharides. Macromolecules: 2002b; 35:9545-9550.
45. Kim, B., Peppas, N.A., Synthesis and characterization of pHsensitive glycopolymers for oral drug delivery systems. J. Biomater. Sci. Polym.: 2002a; 13: 1271-1281.
46. Kiran Sonaje, Yi-Jia Chen, Hsin-Lung Chen, Shiaw-Pyng Wey, Jyuhn-Huarng Juang, Ho-Ngoc Nguyen, Chia-Wei Hsu , Kun-Ju Lin , Hsing-Wen Sung. Enteric-coated capsules filled with freeze-dried chitosan/poly (g-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials:2010;31: 3384-3394
47. Kisel, M.A., Kulik, L.N., Tsybovsky, I.S., Vlasov, A.P., Vorb'yov, M.S., Kholodova, E.A., Zabarovskaya, Z.V. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int. J. Pharm. :2001; 216:105-114
48. Kleir, J., Peppas, N.A. Complex-forming hydrogels sensitive to physiological conditions. Proc. Adv. Biomed. Polym.: 1989; 1:107-109.
49. Lambkin, I., Pinilla, C. Targeting approaches to oral drug delivery. Exp. Op. Bio. Ther.: 2002; 2 (1):67-73.
50. Lee, V.H.L., Kashi, S.D., Grass, G.M., Rubas, W. Oral route of protein and peptide drug delivery. In: Lee, V.H.L. (Ed.), Peptide and Protein Drug Delivery. Marcel Dekker, New York: 2000; pp. 691-740.
51. Lowman, A.M., Cowans, B.A., Peppas, N.A. Investigation of interpolymer complexation in swollen polyelectolyte networks using solidstateNMR spectroscopy. J. Polym. Sci. B: Polym. Phys.:2000; 38: 2823- 2831.
52. Lowman, A.M., Morishita, M., Kajita, M., Nagai, T., Peppas, N.A. Oral delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci.:1999; 88: 933-937.
53. M. Gordberg, I. Gomez-Orellana, Challenge for the oral delivery of macromolecules, Nat. Rev., Drug Discov. :2003;2: 289-295
54. M. Higaki, M. Higaki, M. Kameyama, M. Udagawa, Y. Ueno, Y. Yamaguchi, R. Igarashi, T. Ishihara, Y.Mizushima, Transdermal delivery of CaCO3-nanoparticles containing insulin, Diabetes Technol. Ther.: 2006; 8: 369-374.
55. M. Katsuma, S. Watanabe, H. Kawai, S. Takemura, K. Sako, Effect of absorption promoters on insulin absorption through colontargeted delivery, Int. J. Pharm. :2005; 307: 156-162
56. M. Morishita, I. Morishita, K. Takayama, Y. Machida, T. Nagai, Site dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin.Biol. Pharm. Bull. :1993;16: 68-72
57. M. Morishita, J.M. Barichello, K. Takayama, Y. Chiba, S. Tokiwa, T. Nagai, Pluronic® F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin, Int. J. Pharm. :2001;212: 289-293
58. M.A. Kisel, L.N. Kulik, I.S. Tsybovsky, A.P. Vlasov,M.S. Vorob'yov, E.A. Kholodova, Z.V. Zabarovskaya, Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat, Int. J. Pharm. :2001;216: 105-114.
59. M.P. Summers, Recent Advances in Drug Delivery, Pharm. J.: 1983.;230:643-645.
60. M.R. Prausnitz, S.Mitragotri, R. Langer, Current status and future potential of transdermal drug delivery, Nat. Rev., Drug Discov.: 2004;3: 115-124
61. Madsen, F., Peppas, N.A. Complexation graft copolymer networks: swelling properties, calcium binding and proteolytic enzyme inhibition. Biomaterials:1999; 20: 1701-1708
62. Mahkam, M., Allahverdipoor, M., Mohammadi, R., Ranaei- Siadat, S.O., Rashidi, M.R., Davaran, S., Barshan, M., Ranaei-Siadat, S.E. An oral delivery system for insulin. J. Bioact. Compat. Polym.: 2006; 21:135-148.
63. Marschsütz, M.K., Caliceti, P., Bernkop-Schnörch, A. Design and in vivo evaluation of an oral delivery system for insulin. Pharm. Res. :2000; 17:1468-1474.
64. Mathiowitz, E., Jacob, J., Jong, Y., Carino, G., Chickering, D., Chaturvedi, P., Santos, C., Vijayaraghavan, K., Montgomery, S., Bassett, M., Morrell, C. Biologically erodable microspheres as potential oral drug delivery systems.: 1997; Nature 386: 410-414.
65. Mounir S. Mesiha, Madiha B. Sidhom, Babatunde Fasipe. Oral and subcutaneous absorption of insulin poly (isobutylcyanoacrylate) nanoparticles. International Journal of Pharmaceutics :2004;288: 289-293
66. N. Kahyap, N. Kumar, M.N.V.R. Kumar, Hydrogels for pharmaceutical and biomedical applications, Crit. Rev. Ther. Drug Carrier Syst.:2005; 22:107-150.
67. N. Kanikkannan, J. Singh, P. Ramarao, Transdermal iontophoretic delivery of bovine insulin and monomeric human insulin analogue, J. Control. Release: 1999; 59: 99-105.
68. Na Zhang, Qi N. Ping, Gui H. Huanga, Wen F. Xua. Investigation of lectin-modified insulin liposomes as carriers for oral administration. International Journal of Pharmaceutics :2005;294:247-259
69. Nordestgard, B.G., Agerholm-Larsen, B., Stender, S.Effect of exogenous hyperinsulinaemia on atherogenesis in cholesterol-fed rabbits. Diabetologia: 1997; 40: 512-520.
70. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med: 2003; 20(11):886-98.
71. P. O'Hara, A.J. Hickey, Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization, Pharm. Res.:2000; 17: 955-961.
72. P. Venugopalan, A. Sapre, N. Venkatesan, S.P. Vyas, Pelleted bioadhesive polymeric nanoparticles for buccal delivery of insulin: preparation and characterization, Pharmazie :2001;56:217-219
73. Peppas, N.A., Keys, K.B., Torres-lugo, M., Lowman, A.M. Poly (ethylene glycol) containing hydrogels in drug delivery. J. Controlled Release: 1999; 62:81-87.
74. Philip F. Builders , Olobayo O. Kunle , Larry C. Okpaku , Modupe I. Builders , Anthony A. Attama , Michael U. Adikwu..Preparation and evaluation of mucinated sodium alginate microparticles for oral delivery of insulin. European Journal of Pharmaceutics and Biopharmaceutics :2008;70 :777-783
75. Ponchel, P., Irache, J.M. Specific and non-specific bioadhesive- materisive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. :1998;34: 191- 219.
76. Q. Zhang, Z. Shen, T. Nagai, Prolonged hypoglycemic effect of insulinloaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats, Int. J. Pharm. :2001;218: 75-80.
77. Qian, F., Cui, F., Ding, J., Tang, C., Yin, C. Chitosan graft copolymer nanoparticles for oral protein drug delivery: preparation and characterization. Biomacromolecules: 2006; 7: 2722-2727.
78. R. Hanas, J. Ludvigsson, Experience of pain from insulin injections and needlephobia in young patients with IDDM, Pract. Diabetes Int. :2005;14 :95-99.
79. R. Mitra, I. Pezron, W.A. Chu, A.K. Mitra, Lipid emulsions as vehicles for enhanced nasal delivery of insulin, Int. J. Pharm. :2000;205:127-134
80. R. Mitra, I. Pezron, Y. Li, A.K. Mitra, Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids, Int. J. Pharm. :2001;217:25-31.
81. R. Srinivasan, S.K. Jain, Insulin delivery through the ocular route, Drug Deliv: 1998;5: 53-57.
82. R.I. Mahato, A.S. Narang, L. Thoma, D.D. Miller, Emerging trends in oral delivery of peptide and proteins, Crit. Rev. Ther. Drug Carr. Syst. :2003;20: 153-214.
83. R.J. Mrsny, The colon as a site for drug delivery, J. Control. Release: 1992; 22: 15-34.
84. R.S. Spangler, Insulin administration via liposomes, Diabetes Care: 1990; 13:911-922.
85. R.U. Agu,M.I. Ugwoke,M. Armand, R. Kinget, N. Verbeke, The lung as a route for systemic delivery of therapeutic proteins and peptides, Respir. Res.: 2001;2: 198-209.
86. Ritschel, W.A. Microemulsions for improved peptide absorption from the gastrointestinal tract. Methods Find. Exp. Clin. Pharmacol.: 1991; 13:205-220.
87. Robinson, D.N., Peppas, N.A. Preparation and characterization of pH-responsive poly(methacrylic acid-g-ethylene glycol) nanospheres. Macromolecules: 2002;35:3668-3674.
88. S. Eaimtrakarn, Y.V. Rama Prasad, T. Ohno, et al., Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats, J. Drug Target: 2002; 10:255-260.
89. S. Haupt, A. Rubinstein, The colon as a possible target for orally administered peptide and protein drugs, Crit. Rev. Ther. Drug Carr. Syst. :2002;19:499-551
90. S Lee, B. Snyder, R.E. Newnham, N.B. Smith, Non-invasive ultrasonic transdermal insulin delivery in rabbits using the light-weight cymbal array, Diabetes Technol. Ther.: 2004; 6:808-815.
91. S. Mitragotri, J. Kost, Low-frequency sonophoresis. A review, Adv. Drug Deliv. Rev. :2004;56: 589-601
92. Saffran, M., Kumar, G.S., Neckers, D.C., Pena, J., Jones, R.H., Field, J.B. Biodegradable azopolymer coating for oral delivery of peptide drugs. Biochem. Soc. Trans. :1990;18:752-754.
93. Saffran, M., Pansky, B., Budd, G.C., Williams, F.E. Insulin and the gastrointestinal tract. J. Control. Release: 1997; 46: 89-98.
94. Sarmento, B., Ferreira, D.C., Jorgensen, L., van de Weert, M. Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. Eur. J. Pharm. Biopharm.: 2007; 65:10- 17.
95. Sastry S.V., Nyshadham, J.R., Fix, J.A. Recent technological advances in oral drug delivery-a review: 2000; 3:138-145.
96. Schilling, R.J., Mitra, A.K. Degradation of insulin by trypsin and alphachymotrypsin. Pharm. Res. :1991; 8:721-727.
97. Senel, S., Capan, Y., Sargon, M.F., Ikinci, G., Solpan, D., Guven, O., Bodde, H.E., Hincal, A.A... Enhancement of transmucosal permeation of morphine sulfate by sodium glycodeoxycholate in vitro. J. Controlled Release: 1997; 45:153-162.
98. Shen, W.-C. Oral peptide and protein delivery: unfulfilled promises? Drug Discov. Today: 2003; 8 (14):607-608.
99. Simon, M., Behrens, I., Dailey, L.A., Wittmar, M., Kissel, T. Nanosized insulin-complexes based on biodegradable amine-modified graft polyesters poly[(vinyl-3-(diethylamino)-propylcarbamate-co-(vinyl acetate)- co-(vinyl alcohol)]-graft-poly(l-lactic acid): protection against enzymatic degradation, interaction with Caco-2 cell monolayers, peptide transport and cytotoxicity. Eur. J. Pharm. Biopharm. :2007;66: 165-172.
100. Soppimath, K.S., Aminabhavi, T.M., Kulkarni, A.R., Rudzinski,W.E.. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release:2001; 70: 1-20.
101. Spernath, A., Aserin, A. Microemulsions as carriers for drugs and nutraceuticals. Adv. Colloid Interface Sci.: 2006; 47-64: 128-130.
102. Stacia Furtado, Danielle Abramson, Roxanne Burrill, Gloria Olivier, Celinda Gourd, Emily Bubbers, Edith Mathiowitz. Oral delivery of insulin loaded poly(fumaric-co-sebacic) anhydride microspheres. International Journal of Pharmaceutics: 2008; 347:149-155.
103. Torres-lugo, M., Garcia, M., Record, R., Peppas, N.A. pH sensitive hydrogel as gastrointestinal tract absorption enhancers: transport mechanisms of salmon calcitonin and other model molecules using the caco-2 cell model. Biotechnol. Prog.: 2002; 18:612-616.
104. V. Agarwal, I.K. Reddy, M.A. Khan, Oral delivery of proteins: effect of chicken and duck ovomucoid on the stability of insulin in the presence of a- chymotrypsin and trypsin, Pharm. Pharmacol. Commun. :2000;6: 223-227
105. W.T. Cefalu, Concept, strategies, and feasibility of noninvensive insulin delivery, Diabetes Care: 2004; 27: 239-246.
106. Wu, Z.-H., Ping, Q.-N., Wei, Y., Lai, J.-M. Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice. Acta Pharm. Sin. :2007;25:966-972
107. X.J. Chen, J.B. Zhu, G.J. Wang, M.X. Zhou, F.M. Xin, N. Zhang, C.X. Wang, Y.N. Xu, Hypoglycemic efficacy of pulmonary delivered insulin dry powder aerosol in rats, Acta Pharmacol. Sin. :2002;23: 467-470
108. Y. Sudhakar, K. Kuotsu, A.K. Bandyopadhyay, Buccal bioadhesive drug delivery - a promising option for orally less efficient drugs, J. Control. Release: 2006; 114:15-40.
109. Y. Zhang, X.G. Jiang, J. Yao, Nasal absorption enhancement of insulin by sodium deoxycholate in combination with cyclodextrins, Acta Pharmacol. Sin. :2001;22:1051-1056
110. Y.C. Lee, P. Simamora, S. Pinsuwan, S.H. Yalkowsky, Review on the systemic delivery of insulin via the ocular route, Int. J. Pharm. :2002;233: 1-18.
111. Y.C. Lee, S.H. Yalkowsky, Systemic absorption of insulin froma Gelfoam® ocular device, Int. J. Pharm. :1999;190: 35-40
112. Y.Y. Huang, C.H. Wang, Pulmonary delivery of insulin by liposomal carriers, J. Control. Release:2006.113: 9-14
113. Yoshida, H., Lehr, C.M., Kok, W., Juninger, H.E., Verhoef, J.C., Bouwstra, J.A. Niosomes for oral delivery of peptide drugs. J. Control. Release :1992;21: 145-154
114. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract: 1999; 46(3):239-46.